Live Breaking News & Updates on Medexus Pharmaceuticals Investor Update

Medexus Submits Application to List on the Nasdaq
TORONTO, CHICAGO and MONTREAL, Jan. 21, 2021 Medexus Pharmaceuticals Inc. (the “
Company” or
“Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)
 announced today that it has submitted its application to list on The Nasdaq Capital Market® (the “
Nasdaq”).
Ken d’Entremont, Chief Executive Officer of Medexus, commented, “The submission of our application to list on the Nasdaq marks a significant milestone for Medexus. We believe we now meet the initial listing requirements, which reflects the success of our ongoing efforts to create a highly scalable business platform with a diversified and growing product portfolio across North America. In fact, we have grown at a 129% CAGR over the past 3 fiscal years alone and are generating very strong cash flow. Given our current trajectory and growth of our U.S-based business that now accounts for more than 74% of total revenues, management an ....

United States , Roland Boivin , Company Or Medexus , Crescendo Communications , Frankfurt Stock Exchange , Medexus Pharmaceuticals Investor , While The Company , Medexus Pharmaceuticals Inc , Venture Exchange , Customer Service , Regulation Services Provider , Medexus Pharmaceuticals , Nasdaq Capital Market , Chief Executive Officer , Frankfurt Stock , Investor Update Webinar , Medexus Pharmaceuticals Investor Update , North American , Chief Executive Officer Medexus Pharmaceuticals , Chief Financial Officer Medexus Pharmaceuticals , Tina Byers Adelaide Capital Tel , Forward Looking , ஒன்றுபட்டது மாநிலங்களில் , ரோலண்ட் போவின் , பிறை தகவல்தொடர்புகள் , பிராங்க்ஃபர்ட் ஸ்டாக் பரிமாற்றம் ,